Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

95P - Immune infiltrate in malignant tumors treated with nivolumab and/or ipilimumab


09 Dec 2020


e-Poster Display Session


Korinna Joehrens


Annals of Oncology (2020) 31 (suppl_7): S1452-S1456. 10.1016/annonc/annonc393


K. Joehrens

Author affiliations

  • Universitaetsklinikum Carl Gustav Carus Dresden, Dresden/DE

Abstract 95P


In this study, the known components of the different immune responses (TH1, TH2, Treg) as well as the PD-L1 status of the tumor (TC) and immune cells (IC) were evaluated in a collective of malignant tumors treated with nivolumab and/or ipilimumab.


Forty-two (42) cases of head and neck squamous cell carcinomas (HNSCC), 104 malignant melanomas (MM), and 50 non-small-cell lung cancers (NSCLC) were investigated by immunohistochemistry for CD3, CD4, CD8, T-BET, GATA3, FOXP3, CD20, IRF4, and PD-L1 expression.


The expression of PD-L1 in TCs of HNSCC was similar in patients with progressive disease (PD), stable disease (SD) or partial response (PR), but differed regarding tumor-infiltrating lymphocytes (TIL’s). Patients with SD or PR exhibited more PD-L1 positive TILs (30%) than patients with PD (5% cases). In 9/42 cases TCs expressed GATA3, in these cases the immune infiltrate contained significantly more T-BET expressing T-cells than in the other cases. In 70% of the MM the TCs expressed IRF4 inducing a TH2 response, thus, most of these cases exhibited an immune infiltrate with features of TH2 response. In NSCLC a prominent immune infiltrate of CD20-positive cells at the tumor invasion front was observed in 40/50 cases (88.9%). This can be explained by the fact that the lungs have direct ant intensive contact with pathogens leading to two overlapping immune reactions.


The composition of the immune infiltrate depends on the tumor localization. In HNSCC the predictive value of PD-L1 expression in tumor cells was lower than PD-L1 expression in TILs.

Legal entity responsible for the study

Korinna Joehrens, Ioannis Anagnostopoulos.




K. Joehrens: Research grant/Funding (self): BMS.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.